Axogen Shares Drop After Pricing $124M Upsized Offering - AXGN

Axogen Inc. shares fell 8.7% to $15.30 on January 22, 2026, following the company's announcement of a upsized underwritten public offering priced at $16.00 per share. The offering raised $124 million through the sale of 7.75 million new shares, increasing from an initial plan of $90 million. The move comes amid ongoing clinical development for its nerve repair products, including AxoGen’s Avance Nerve Graft. The stock declined after market open, reflecting investor concern over dilution and near-term cash needs. Axogen stated the proceeds will fund research, commercial activities, and general corporate purposes. The offering was led by Jefferies and Cowen, with no existing shareholders participating in the placement. The company’s market capitalization stands at approximately $680 million as of January 22, 2026. Trading volume surged to 2.1 million shares, more than triple the 30-day average.